Derek Manas
YOU?
Author Swipe
View article: 184 Experience of Hypothermic Oxygenated Machine Perfusion for Liver Transplantation and Ex-vivo Liver Resection-largest reported single centre experience in the UK
184 Experience of Hypothermic Oxygenated Machine Perfusion for Liver Transplantation and Ex-vivo Liver Resection-largest reported single centre experience in the UK Open
Background Hypothermic oxygenated machine perfusion (HOPE) is being increasingly utilised in deceased donor liver transplantation to recondition expanded-criteria livers prior to transplantation as well as reducing night time liver transpl…
View article: 168 Pancreas transplant outcomes after allocation though the NHSBT pancreas fast-track scheme (FTS)
168 Pancreas transplant outcomes after allocation though the NHSBT pancreas fast-track scheme (FTS) Open
Background The fast-track pancreas scheme (FTS) was brought in to improve pancreas utilisation. It created a scheme for the allocation of pancreas grafts not yet allocated at the time retrieval commenced. There are no previous reports of p…
View article: 80 Selective internal radiotherapy (SIRT) versus Hepatic artery embolization (HAE) for the treatment of neuroendocrine liver metastases
80 Selective internal radiotherapy (SIRT) versus Hepatic artery embolization (HAE) for the treatment of neuroendocrine liver metastases Open
Introduction Liver-directed therapies are an important component of palliative control of disease burden and carcinoid syndrome for unresectable liver metastases of neuroendocrine tumours. Hepatic artery embolization (HAE) and selective in…
View article: Heart Transplantation and Donation After Circulatory Death in Children. A Review of the Technological, Logistical and Ethical Framework
Heart Transplantation and Donation After Circulatory Death in Children. A Review of the Technological, Logistical and Ethical Framework Open
Heart transplant for adults following Donation after Circulatory Death (DCD) is well established in many parts of the world, including the United Kingdom (UK). Small child DCD hearts have now been recovered in the UK and internationally ut…
View article: Guidelines Development Group for the British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma
Guidelines Development Group for the British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma Open
View article: Severe Cholestasis Predicts Recurrent Primary Sclerosing Cholangitis Following Liver Transplantation
Severe Cholestasis Predicts Recurrent Primary Sclerosing Cholangitis Following Liver Transplantation Open
INTRODUCTION: Primary sclerosing cholangitis (PSC) may reoccur following liver transplantation (LT), and the diagnosis established once imaging studies demonstrate the diagnostic cholangiographic appearance. To evaluate whether the develop…
View article: Does Time to Asystole in Donors After Circulatory Death Impact Recipient Outcome in Liver Transplantation?
Does Time to Asystole in Donors After Circulatory Death Impact Recipient Outcome in Liver Transplantation? Open
Background. The agonal phase can vary following treatment withdrawal in donor after circulatory death (DCD). There is little evidence to support when procurement teams should stand down in relation to donor time to death (TTD). We assessed…
View article: The impact of time to death in donors after circulatory death on recipient outcome in simultaneous pancreas-kidney transplantation
The impact of time to death in donors after circulatory death on recipient outcome in simultaneous pancreas-kidney transplantation Open
View article: Multi-Centre UK Analysis of Simultaneous Pancreas and Kidney (SPK) Transplant in Recipients With Type 2 Diabetes Mellitus
Multi-Centre UK Analysis of Simultaneous Pancreas and Kidney (SPK) Transplant in Recipients With Type 2 Diabetes Mellitus Open
90% of the UK diabetic population are classified as T2DM. This study aims to compare outcomes after SPK transplant between recipients with T1DM or T2DM. Data on all UK SPK transplants from 2003–2019 were obtained from the NHSBT Registry ( …
View article: Racial disparities in outcomes after liver transplantation in the UK: registry analysis
Racial disparities in outcomes after liver transplantation in the UK: registry analysis Open
View article: British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma
British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma Open
These guidelines for the diagnosis and management of cholangiocarcinoma (CCA) were commissioned by the British Society of Gastroenterology liver section. The guideline writing committee included a multidisciplinary team of experts from var…
View article: Impact of Hepatitis E Virus Screening in the UK Deceased Organ Donor Population
Impact of Hepatitis E Virus Screening in the UK Deceased Organ Donor Population Open
Universal Hepatitis E Virus (HEV) screening of deceased organ donors was implemented by the UK national organ procurement organisation in October 2017. Donor testing for HEV infection is done post-transplant; detection of HEV ribonucleic a…
View article: International consensus recommendations on face transplantation: A 2-step Delphi study
International consensus recommendations on face transplantation: A 2-step Delphi study Open
View article: 1221 Recipient Outcomes After Simultaneous Pancreas and Kidney Transplant Delineated by Donor eGFR
1221 Recipient Outcomes After Simultaneous Pancreas and Kidney Transplant Delineated by Donor eGFR Open
Aim This study aimed to assess if the use of kidneys with a decreased eGFR had an adverse effect on patient and graft survival. Method Data on all UK SPKT’s from 2001-2021 were obtained from the NHSBT UK Transplant Registry (n = 2,631). Ca…
View article: Fibrin-based haemostatic agents for reducing blood loss in adult liver resection
Fibrin-based haemostatic agents for reducing blood loss in adult liver resection Open
The evidence for the outcomes in both comparisons (FBHAs versus no intervention and FBHAs versus non-FBHAs) was of very low certainty (or low certainty in one instance) and cannot justify the routine use of FBHAs to reduce blood loss in ad…
View article: Incidental lymphadenopathy in renal transplantation
Incidental lymphadenopathy in renal transplantation Open
There are currently no published guidelines on the management of incidentally enlarged iliac LNs during transplantation. Current literature suggests that clinically significant lymphadenopathy needs to be investigated in all patients. Base…
View article: O041 Recipient outcomes after simultaneous pancreas and kidney transplant delineated by donor EGFR
O041 Recipient outcomes after simultaneous pancreas and kidney transplant delineated by donor EGFR Open
Introduction This study aimed to assess if the use of kidneys from donors with a decreased eGFR had an adverse effect on patient and graft survival. Methods Data on all UK SPKT's from 2001-2021 were obtained from the NHSBT UK Transplant Re…
View article: O004 Impact of normothermic regional perfusion on recipient outcomes after simultaneous pancreas and kidney transplantation – a UK analysis from the NHSBT Pancreas Advisory Group
O004 Impact of normothermic regional perfusion on recipient outcomes after simultaneous pancreas and kidney transplantation – a UK analysis from the NHSBT Pancreas Advisory Group Open
Introduction A quarter of UK SPK transplants are from Deceased Cardiac Donors(DCD), with an increasing number recovered following in-situ normothermic regional perfusion(NRP). The aim of this study was to review the UK experience of SPK tr…
View article: O037 VEGF-A: a potential prognostic biomarker for donor liver viability
O037 VEGF-A: a potential prognostic biomarker for donor liver viability Open
Introduction Waitlist mortality for liver transplant recipients may be tackled by increasing graft utilisation from marginal donors. At present, there are no reliable methods of assessing the quality of potential donor grafts prior to post…
View article: Data Supplement from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
Data Supplement from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival Open
Data Supplement from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
View article: Supplementary Figure Legends from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
Supplementary Figure Legends from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival Open
Supplementary Figure Legends
View article: Supplementary Tables 1-2 from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
Supplementary Tables 1-2 from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival Open
Supplementary Tables 1-2. Supplementary Table 1. Clinical features of the subset of patients receiving palliative TACE as first line therapy Supplementary Table 2 - Tumour Factors associated with survival in cohort two
View article: Supplementary Methods from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
Supplementary Methods from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival Open
Supplementary Methods
View article: Supplementary Tables 1-2 from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
Supplementary Tables 1-2 from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival Open
Supplementary Tables 1-2. Supplementary Table 1. Clinical features of the subset of patients receiving palliative TACE as first line therapy Supplementary Table 2 - Tumour Factors associated with survival in cohort two
View article: Supplementary Figures 1-11 from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
Supplementary Figures 1-11 from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival Open
Supplementary Figures 1-11. Supplementary Figure 1. DNA-PK expression and tumour specific PRKDC locus amplification Supplementary Figure 2. DDR gene expression in HCC cells Supplementary Figure 3: DDR protein expression and activity in HCC…
View article: Data from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
Data from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival Open
Purpose: Therapy resistance and associated liver disease make hepatocellular carcinomas (HCC) difficult to treat with traditional cytotoxic therapies, whereas newer targeted approaches offer only modest survival benefit. We focused …
View article: Supplementary Figure Legends from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
Supplementary Figure Legends from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival Open
Supplementary Figure Legends
View article: Data Supplement from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
Data Supplement from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival Open
Data Supplement from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
View article: Supplementary Figures 1-11 from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
Supplementary Figures 1-11 from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival Open
Supplementary Figures 1-11. Supplementary Figure 1. DNA-PK expression and tumour specific PRKDC locus amplification Supplementary Figure 2. DDR gene expression in HCC cells Supplementary Figure 3: DDR protein expression and activity in HCC…
View article: Data from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival
Data from DNA-PK—A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival Open
Purpose: Therapy resistance and associated liver disease make hepatocellular carcinomas (HCC) difficult to treat with traditional cytotoxic therapies, whereas newer targeted approaches offer only modest survival benefit. We focused …